These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19427380)

  • 1. Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo.
    Ries C; Lucas S; Heim R; Birk B; Hartmann RW
    J Steroid Biochem Mol Biol; 2009 Sep; 116(3-5):121-6. PubMed ID: 19427380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.
    Grombein CM; Hu Q; Rau S; Zimmer C; Hartmann RW
    Eur J Med Chem; 2015 Jan; 90():788-96. PubMed ID: 25528333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
    Müller-Vieira U; Angotti M; Hartmann RW
    J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):259-70. PubMed ID: 15985365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of a whole-cell based medium throughput screening system for the discovery of human aldosterone synthase (CYP11B2) inhibitors: old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
    Hakki T; Hübel K; Waldmann H; Bernhardt R
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):120-8. PubMed ID: 21193036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells.
    Ehmer PB; Bureik M; Bernhardt R; Müller U; Hartmann RW
    J Steroid Biochem Mol Biol; 2002 Jun; 81(2):173-9. PubMed ID: 12137808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: a new class of potent and selective aldosterone synthase inhibitors.
    Grombein CM; Hu Q; Heim R; Rau S; Zimmer C; Hartmann RW
    Eur J Med Chem; 2015 Jan; 89():597-605. PubMed ID: 25462268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.
    Yin L; Hu Q; Emmerich J; Lo MM; Metzger E; Ali A; Hartmann RW
    J Med Chem; 2014 Jun; 57(12):5179-89. PubMed ID: 24899257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human.
    Cerny MA; Csengery A; Schmenk J; Frederick K
    J Steroid Biochem Mol Biol; 2015 Nov; 154():197-205. PubMed ID: 26303746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.
    Lucas S; Heim R; Ries C; Schewe KE; Birk B; Hartmann RW
    J Med Chem; 2008 Dec; 51(24):8077-87. PubMed ID: 19049427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
    Ulmschneider S; Müller-Vieira U; Mitrenga M; Hartmann RW; Oberwinkler-Marchais S; Klein CD; Bureik M; Bernhardt R; Antes I; Lengauer T
    J Med Chem; 2005 Mar; 48(6):1796-805. PubMed ID: 15771425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors.
    Cai TQ; Stribling S; Tong X; Xu L; Wisniewski T; Fontenot JA; Struthers M; Akinsanya KO
    J Pharmacol Toxicol Methods; 2015; 71():137-46. PubMed ID: 25304940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activity.
    Meyers K; Cogan DA; Burke J; Arenas R; Balestra M; Brown NF; Chen Z; Cerny MA; Clifford HE; Colombo F; Fader L; Frederick KS; Guo X; Goldberg D; Hornberger KR; Kugler S; Lord J; Marshall DR; Moss N; Parmentier JH; Richman JR; Schmenk J; Weldon SM; Yu M; Zhang M
    Bioorg Med Chem Lett; 2018 Mar; 28(5):979-984. PubMed ID: 29254646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
    Bogman K; Schwab D; Delporte ML; Palermo G; Amrein K; Mohr S; De Vera Mudry MC; Brown MJ; Ferber P
    Hypertension; 2017 Jan; 69(1):189-196. PubMed ID: 27872236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a high-throughput assay for aldosterone synthase inhibitors using high-performance liquid chromatography-tandem mass spectrometry.
    Yurek D; Yu L; Schrementi J; Bell MG; McGee J; Kowala M; Kuo MS; Wang J
    Anal Biochem; 2014 Oct; 462():44-50. PubMed ID: 24959941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Aldosterone Synthase Inhibitor FAD286 is Suitable for Lowering Aldosterone Levels in ZDF Rats but not in db/db Mice.
    Hofmann A; Brunssen C; Peitzsch M; Balyura M; Mittag J; Frenzel A; Jannasch A; Brown NF; Weldon SM; Gueneva-Boucheva KK; Eisenhofer G; Bornstein SR; Morawietz H
    Horm Metab Res; 2017 Jun; 49(6):466-471. PubMed ID: 28427090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imidazopyridyl compounds as aldosterone synthase inhibitors.
    Whitehead BR; Lo MM; Ali A; Park MK; Hoyt SB; Xiong Y; Cai J; Carswell E; Cooke A; MacLean J; Ratcliffe P; Robinson J; Bennett DJ; Clemas JA; Wisniewski T; Struthers M; Cully D; MacNeil DJ
    Bioorg Med Chem Lett; 2017 Jan; 27(2):143-146. PubMed ID: 27979595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
    Voets M; Antes I; Scherer C; Müller-Vieira U; Biemel K; Marchais-Oberwinkler S; Hartmann RW
    J Med Chem; 2006 Apr; 49(7):2222-31. PubMed ID: 16570918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.
    Martin RE; Aebi JD; Hornsperger B; Krebs HJ; Kuhn B; Kuglstatter A; Alker AM; Märki HP; Müller S; Burger D; Ottaviani G; Riboulet W; Verry P; Tan X; Amrein K; Mayweg AV
    J Med Chem; 2015 Oct; 58(20):8054-65. PubMed ID: 26403853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
    Zimmer C; Hafner M; Zender M; Ammann D; Hartmann RW; Vock CA
    Bioorg Med Chem Lett; 2011 Jan; 21(1):186-90. PubMed ID: 21129965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
    Voets M; Antes I; Scherer C; Müller-Vieira U; Biemel K; Barassin C; Marchais-Oberwinkler S; Hartmann RW
    J Med Chem; 2005 Oct; 48(21):6632-42. PubMed ID: 16220979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.